Enbrel® (etanercept) is a prescription medicine used to treat five chronic diseases, including moderate to severe rheumatoid arthritis. These highlights do not include all the information needed to use Enbrel safely and effectively. See full prescribing information for Enbrel. Enbrel® (etanercept). What is Enbrel (etanercept) and what is it used for? of Product Characteristics ( SPC) for Enbrel these can be found at the electronic Medicines Compendium.
|Published (Last):||3 January 2004|
|PDF File Size:||6.82 Mb|
|ePub File Size:||4.62 Mb|
|Price:||Free* [*Free Regsitration Required]|
Search for a Medicine
For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies. To find relevant articles please visit here to pick a cluster. Powder and solution for injection. Etanercept is a human tumour necrosis factor receptor slc Fc fusion protein.
It is a competitive inhibitor of TNF binding to cell surface receptors. Treatment of active rheumatoid arthritis in adults when the response to disease modifying antirheumatic drugs, including methotrexate unless contraindicatedhas been inadequate. Treatment of active polyarticular-course juvenile chronic arthritis in children aged four to 17 years who have had an inadequate response to, or who have proved intolerant of, methotrexate.
Hypersensitivity to active substance or excipients; sepsis or risk of sepsis.
Treatment should not be initiated in embrel with active infections, including chronic or localised infections. Treatment should be initiated and supervised by specialist physicians. Enbrel 25mg is reconstituted with 1ml water for injections. Adults, recommended dose is 25mg etanercept administered twice weekly as a subcutaneous injection. Elderly 65 years and overno dosage adjustment required. Children and adolescents four to 17 years0.
Children under four years, etanercept has not been studied. Renal and hepatic impairment, no dose adjustment required. Pregnancy, use is not recommended. Women of child-bearing potential should be advised not to get pregnant during use. Lactation, excretion in human milk unknown see SPC. Ebrel dose-limiting toxicities observed in trials. Patients enbrsl develop a new infection while undergoing treatment apc be monitored closely. Discontinue treatment if a serious infection develops.
Caution needed when considering use in patients with a history of recurring infections or with envrel conditions which may predispose to infections, such as advanced or poorly controlled diabetes.
Patients with significant exposure to varicella virus should temporarily discontinue etanercept and be considered for prophylactic treatment with varicella zoster immune globulin. Live vaccines should not be given concurrently with etanercept. Juvenile chronic arthritis patients should, if possible, be brought up to date with all immunisations prior to initiating therapy. The long term safety of etanercept in combination with other disease-modifying antirheumatic drugs has not been established.
Interactions between etanercept and other drugs have not been evaluated in formal studies. Adults, injection site enhrel, upper respiratory tract infections. No increase in the incidence of serious infections was observed in trials. In postmarketing reports, serious infections have been reported. Impact of long term treatment on the development of autoimmune disease is unknown.
See SPC for details of other undesirable effects. Juvenile chronic arthritis, in general, undesirable effects similar in frequency and type to those seen in adults. Headache, nausea, abdominal pain and vomiting were reported more commonly in juvenile chronic arthritis patients than in adults in trials. Wyeth says that supplies of etanercept are currently limited by manufacturing constraints and nebrel unlikely to be sufficient to treat all suitable adult rheumatoid arthritis patients.
To ensure continuity of supply the company is maintaining a record of patients prescribed etanercept by initials epc and a special form has been designed to accompany each order. For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment. Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.
Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts. Skip to main content Skip to navigation.
Enbrel injection | News | Pharmaceutical Journal
Sign In Register Enbrsl pharmaceutical-journal. Search the site Search. Join Subscribe or Register Existing user? Perspective article Review article Research article. Latest Role of dual and triple fixed-dose combination inhalers in the treatment of chronic obstructive pulmonary disease 5 NOV Latest Celebrating a year of career highlights 12 DEC Latest views Mark Lyonette: Have your say For enbreel, please login or register as a user and agree to our Community Guidelines.
Recommended from Pharmaceutical Press. Enter email address Submit.